DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?! Background and Main Cardiovascular Outcomes
4:00 p.m. CT Saturday, June 13
I will review the background to, design of, and main outcomes of the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) in which we showed the SGLT2 inhibitor tested reduced the risk of worsening heart failure and death, and was well tolerated, in patients with heart failure, and reduced ejection fraction (both in individuals with and without diabetes). In the symposium we will show new outcomes data, including data on the effect of dapagliflozin in addition to other glucose-lowering therapies (and none) and on new-onset diabetes.